Blinatumomab

Generic Name
Blinatumomab
Brand Names
Blincyto
Drug Type
Biotech
Chemical Formula
-
CAS Number
853426-35-4
Unique Ingredient Identifier
4FR53SIF3A
Background

Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since b...

Indication

Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to...

Associated Conditions
Precursor B-lymphoblastic leukaemia acute, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
Associated Therapies
-
Clinical Trials
Related News

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

First Posted Date
2022-01-14
Last Posted Date
2024-11-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
35
Registration Number
NCT05192889
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Phase 1
Recruiting
Conditions
ALL, Recurrent, Adult
Interventions
Drug: Blinatumomab
Drug: Venetoclax
First Posted Date
2022-01-10
Last Posted Date
2024-05-22
Lead Sponsor
Goethe University
Target Recruit Count
39
Registration Number
NCT05182385
Locations
🇩🇪

Charité - Campus Benjamin Franklin, Berlin, Germany

🇩🇪

University Hospital of Frankfurt (Main), Frankfurt (Main), Hessen, Germany

🇩🇪

Universitätsklinikum Essen, Essen, Germany

and more 14 locations

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

First Posted Date
2021-08-06
Last Posted Date
2024-12-05
Lead Sponsor
Amgen
Target Recruit Count
287
Registration Number
NCT04994717
Locations
🇦🇺

Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

University of California Irvine, Orange, California, United States

and more 157 locations

ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

Phase 2
Terminated
Conditions
ALL, Childhood
Minimal Residual Disease
Interventions
Drug: Blinatumomab
First Posted Date
2021-03-08
Last Posted Date
2024-01-16
Lead Sponsor
Prof. Christina Peters
Target Recruit Count
3
Registration Number
NCT04785547
Locations
🇳🇴

Oslo University Hospital, Oslo, Norway

🇮🇹

IRCCS Ospedale Pediatrico Bambino Gesù Roma, Roma, Italy

🇵🇱

Nicolaus Copernicus University Collegium Medicum, Bydgoszcz, Poland

and more 11 locations

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

First Posted Date
2021-02-09
Last Posted Date
2021-09-17
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
25
Registration Number
NCT04746209
Locations
🇺🇸

Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot

Not Applicable
Recruiting
Conditions
Childhood Acute Lymphoblastic Leukemia
Interventions
Drug: Blinatumomab
First Posted Date
2021-01-25
Last Posted Date
2021-01-25
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
180
Registration Number
NCT04723342
Locations
🇷🇺

Almazov National Medical Research Centre, Saint Petersburg, Russian Federation

🇷🇺

Dmitry Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

🇷🇺

National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation

and more 1 locations

Study in Adult Ph-positive ALL

First Posted Date
2020-12-30
Last Posted Date
2020-12-30
Lead Sponsor
Cardiff University
Target Recruit Count
180
Registration Number
NCT04688983

Blinatumomab Bridging Therapy

First Posted Date
2020-09-21
Last Posted Date
2022-04-05
Lead Sponsor
Michael Burke
Target Recruit Count
35
Registration Number
NCT04556084
Locations
🇺🇸

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2020-09-18
Last Posted Date
2024-04-04
Lead Sponsor
Institute of Hematology and Blood Transfusion, Czech Republic
Target Recruit Count
27
Registration Number
NCT04554485
Locations
🇨🇿

University Hospital Hradec Kralove,The 4th Department of Internal Medicine - Hematology, Hradec Králové, Czechia

🇨🇿

University Hospital Olomouc, Hematooncology Clinic, Olomouc, Czechia

🇨🇿

University Hospital Ostrava, Hematooncology Clinic, Ostrava, Czechia

and more 2 locations

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

First Posted Date
2020-09-14
Last Posted Date
2024-10-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
300
Registration Number
NCT04546399
Locations
🇺🇸

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States

🇺🇸

Corewell Health Dearborn Hospital, Dearborn, Michigan, United States

🇺🇸

Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States

and more 200 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy